Pictet Asset Management Holding SA Purchases 44,500 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Pictet Asset Management raised its Regeneron stake by 13.8%, buying 44,500 shares to own 367,870 shares (about 0.35% of the company) valued at roughly $284.7 million per its latest 13F filing.
• Regeneron won FDA approval for Otarmeni, a gene therapy to restore hearing — the company will provide the therapy free to eligible U.S. patients and reportedly secured three years of tariff relief, though a drug‑pricing/MFN deal could weigh on margins.
• Analyst sentiment is broadly positive with a consensus rating of "Moderate Buy" and an average target of $825.35, while some firms have raised targets up to about $950.

Pictet Asset Management Holding SA raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 367,870 shares of the biopharmaceutical company's stock after purchasing an additional 44,500 shares during the period. Pictet Asset Management Holding SA owned approximately 0.35% of Regeneron Pharmaceuticals worth $284,716,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Meyer Handelman Co. raised its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the fourth quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company's stock valued at $2,221,000 after purchasing an additional 18 shares during the last quarter. CoreCap Advisors LLC grew its position in Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company's stock worth $134,000 after purchasing an additional 20 shares in the last quarter. Whittier Trust Co. increased its stake in Regeneron Pharmaceuticals by 5.9% in the 4th quarter. Whittier Trust Co. now owns 357 shares of the biopharmaceutical company's stock valued at $277,000 after buying an additional 20 shares during the last quarter. Strait & Sound Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.5% in the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company's stock worth $353,000 after buying an additional 21 shares during the last quarter. Finally, Parkside Financial Bank & Trust grew its holdings in shares of Regeneron Pharmaceuticals by 14.8% in the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company's stock valued at $92,000 after acquiring an additional 21 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Zacks Research downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 6th. Evercore lifted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, April 11th. JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an "overweight" rating in a research note on Monday, February 2nd. Finally, Barclays assumed coverage on shares of Regeneron Pharmaceuticals in a report on Friday, March 6th. They issued an "overweight" rating and a $923.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $825.35.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni (lunsotogene parvec-cwha), the first gene therapy to restore hearing — pivotal CHORD data showed ~80% met the primary endpoint and 42% achieved normal hearing on longer follow‑up, marking a breakthrough product and validating Regeneron’s genetic‑medicine efforts. Read More.
• Positive Sentiment: Analyst support: TD Cowen raised its price target to $960 (buy) and Cantor Fitzgerald reaffirmed an overweight rating with an $800 target — institutional upgrades can support upside as investors re‑rate growth prospects. Read More.
• Positive Sentiment: Regeneron reportedly secured tariff relief from the U.S. government for three years as part of the deal, which mitigates some cost headwinds and is a near‑term financial benefit. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major access/PR move that increases uptake and public goodwill but has ambiguous near‑term revenue implications. Read More.
• Neutral Sentiment: Q1 preview / estimates: Research outlets (Zacks) are parsing Wall Street’s revenue and key‑metric estimates ahead of quarterly reporting — results will be important for near‑term stock direction. Read More.
• Neutral Sentiment: CEO Leonard Schleifer said Regeneron will provide Otarmeni for free in the U.S. but hasn’t decided on overseas pricing — international price strategy remains uncertain and will affect global revenue potential. Read More.
• Negative Sentiment: Drug‑pricing deal: Regeneron agreed to offer some prescriptions at “most‑favored‑nation” (MFN) prices and to lower U.S. drug costs under the administration deal — investors worry this could compress margins and reduce pricing power across the portfolio. Read More.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $751.57 on Monday. The business has a 50-day simple moving average of $762.84 and a two-hundred day simple moving average of $733.31. The company has a market cap of $79.46 billion, a P/E ratio of 18.08, a P/E/G ratio of 1.67 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts' consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals's revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $12.07 EPS. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.2 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is presently 9.05%.

Insiders Place Their Bets

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director owned 1,703 shares of the company's stock, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,774 shares of company stock valued at $2,942,738 in the last quarter. Corporate insiders own 7.02% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.